California biotechnology firm BioSeek this week said it will profile certain respiratory compounds developed by Canadian drugmaker Inflazyme Pharmaceuticals.
The deal provides BioSeek with an endorsement of its human primary cell-based systems biology approach to drug discovery and additional cash for continued support of its own drug-discovery programs — which in turn could be licensed to outside developers.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Try GenomeWeb Premium now.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
